Literature DB >> 24396159

Clinician's Commentary on Tatham et al.(1.).

Kristen Macdonell1.   

Abstract

Year:  2013        PMID： 24396159      PMCID： PMC3817878          DOI： 10.3138/ptc.2012-06-CC

Source DB:  PubMed          Journal:  Physiother Can        ISSN： 0300-0508            Impact factor:   1.037


× No keyword cloud information.
  6 in total

1.  The efficacy of exercise therapy in reducing shoulder pain related to breast cancer: a systematic review.

Authors:  Barbara Tatham; Jenna Smith; Oren Cheifetz; Jessica Gillespie; Katie Snowden; Jessica Temesy; Lisa Vandenberk
Journal:  Physiother Can       Date:  2013       Impact factor: 1.037

2.  Impairments, activity limitations and participation restrictions 6 and 12 months after breast cancer operation.

Authors:  Anne Kärki; Riitta Simonen; Esko Mälkiä; James Selfe
Journal:  J Rehabil Med       Date:  2005-05       Impact factor: 2.912

Review 3.  Upper-extremity pain disorders in breast cancer.

Authors:  Michael D Stubblefield; Christian M Custodio
Journal:  Arch Phys Med Rehabil       Date:  2006-03       Impact factor: 3.966

Review 4.  Exercise interventions for upper-limb dysfunction due to breast cancer treatment.

Authors:  Margaret L McNeely; Kristin Campbell; Maria Ospina; Brian H Rowe; Kelly Dabbs; Terry P Klassen; John Mackey; Kerry Courneya
Journal:  Cochrane Database Syst Rev       Date:  2010-06-16

5.  The Edmonton Classification System for Cancer Pain: comparison of pain classification features and pain intensity across diverse palliative care settings in eight countries.

Authors:  Cheryl L Nekolaichuk; Robin L Fainsinger; Nina Aass; Marianne J Hjermstad; Anne Kari Knudsen; Pål Klepstad; David C Currow; Stein Kaasa
Journal:  J Palliat Med       Date:  2013-04-24       Impact factor: 2.947

Review 6.  Prognosis of the upper limb following surgery and radiation for breast cancer.

Authors:  Teresa S Lee; Sharon L Kilbreath; Kathryn M Refshauge; Robert D Herbert; Jane M Beith
Journal:  Breast Cancer Res Treat       Date:  2007-09-26       Impact factor: 4.872
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.